Damora Therapeutics is trading 5.6% lower at $19.13 on October 13, 2026, with no clear company-specific announcement explaining the move. - The decline extends the fall from its October 12 close of $20.25. - Healthcare-sector weakness may be contributing amid concerns about potential drug-price regulation and reports of pressure on healthcare shares after Supreme Court questions about medicine markups. - The broad market is nearly flat, offering little explanation for the stock’s decline.